Patents by Inventor Hiroko Habuchi

Hiroko Habuchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7476730
    Abstract: A glycosaminoglycan 6-O-sulfotransferase having an activity of transferring sulfate to a hydroxyl at position 6 of a glycosamine residue of a glycosaminoglycan, which has a ratio of relative activities to substrates satisfying completely desulfated N-acetylated (CDSNAc) heparin/completely desulfated N-resulfated (CDSNS) heparin ?0.05 and a molecular weight as calculated from constituent amino acids of from 53,000 to 58,000 daltons.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: January 13, 2009
    Assignee: Seikagaku Corporation
    Inventors: Hiroko Habuchi, Koji Kimata
  • Patent number: 7396818
    Abstract: The hexuronic acid derivative represented by the following formula 1 or a salt thereof is used as an active ingredient of a heparin/heparan sulfate sulfotransferase inhibitor. In the formula, each of R1, R2, and R3 independently represent(s) SO3? or H which may have a substituent, provided that at least one thereof represents SO3?; X represents OR4, SR4, N(R4)2, or C(R4)3, R4 independently represents H, alkyl, alkenyl, alkynyl, acyl, aryl, or aralkyl group; one of R5 and R6 represents COOH while the other represents H; and the wavy line represents ?-glycosidic bond or ?-glycosidic bond.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: July 8, 2008
    Assignee: Seikagaku Corporation
    Inventors: Koji Kimata, Hiroko Habuchi
  • Publication number: 20070072268
    Abstract: A glycosaminoglycan 6-O-sulfotransferase having an activity of transferring sulfate to a hydroxyl at position 6 of a glycosamine residue of a glycosaminoglycan, which has a ratio of relative activities to substrates satisfying completely desulfated N-acetylated (CDSNAc) heparin/completely desulfated N-resulfated (CDSNS) heparin ?0.05 and a molecular weight as calculated from constituent amino acids of from 53,000 to 58,000 daltons.
    Type: Application
    Filed: December 11, 2006
    Publication date: March 29, 2007
    Inventors: Hiroko Habuchi, Koji Kimata
  • Publication number: 20070066564
    Abstract: The hexuronic acid derivative represented by the following formula 1 or a salt thereof is used as an active ingredient of a heparin/heparan sulfate sulfotransferase inhibitor. In the formula, each of R1, R2, and R3 independently represent(s) SO3? or H which may have a substituent, provided that at least one thereof represents SO3?; X represents OR4, SR4, N(R4)2, or C(R4)3, R4 independently represents H, alkyl, alkenyl, alkynyl, acyl, aryl, or aralkyl group; one of R5 and R6 represents COOH while the other represents H; and the wavy line represents ?-glycosidic bond or ?-glycosidic bond.
    Type: Application
    Filed: May 19, 2004
    Publication date: March 22, 2007
    Inventors: Koji Kimata, Hiroko Habuchi
  • Patent number: 7150981
    Abstract: A glycosaminoglycan 6-O-sulfotransferase having an activity of transferring sulfate to a hydroxyl at position 6 of a glycosamine residue of a glycosaminoglycan, which has a ratio of relative activities to substrates satisfying completely desulfated N-acetylated (CDSNAc) heparin/completely desulfated N-resulfated (CDSNS) heparin?0.05 and a molecular weight as calculated from constituent amino acids of from 53,000 to 58,000 daltons.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: December 19, 2006
    Assignee: Seikagaku Corporation
    Inventors: Hiroko Habuchi, Koji Kimata
  • Publication number: 20040053253
    Abstract: A glycosaminoglycan 6-O-sulfotransferase having an activity of transferring sulfate to a hydroxyl at position 6 of a glycosamine residue of a glycosaminoglycan, which has a ratio of relative activities to substrates satisfying completely desulfated N-acetylated (CDSNAc) heparin/completely desulfated N-resulfated (CDSNS) heparin≧0.05 and a molecular weight as calculated from constituent amino acids of from 53,000 to 58,000 daltons.
    Type: Application
    Filed: December 30, 2002
    Publication date: March 18, 2004
    Inventors: Hiroko Habuchi, Koji Kimata
  • Patent number: 5849722
    Abstract: An oligosaccharide having an affinity for fibroblast growth factor, which is composed of 8 to 18 monosaccharide residues, wherein a principal disaccharide unit comprising L-iduronic acid 2-sulfate and N-sulfo-D-glucosamine and a process for producing the oligosaccharide comprising digesting heparan sulfate.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 15, 1998
    Assignee: Seikagaku Kogyo Kabushiki Kaisha
    Inventors: Hiroko Habuchi, Sakaru Suzuki, Koji Kimata
  • Patent number: 5834282
    Abstract: The present invention provides a heparan sulfate 6-O-sulfotransferase for selectively introducing sulfate group into hydroxyl group at C-6 of glucosamine of heparin and heparan sulfate, having the following properties: (i) sulfate group is selectively transferred from a sulfate group donor to hydroxyl group at C-6 of N-sulfoglucosamine residue; (ii) sulfate group is transferred to CDSNS-heparan, but sulfate group is not transferred to chondroitin and chondroitin-4-sulfate; (iii) optimum reaction pH is in a range of pH 6-7; (iv) optimum ionic strength is in a range of 0.1-0.3 M (in the case of sodium chloride); and (v) the enzyme activity is inhibited by dithiothreitol and adenosine-3',5'-diphosphate, and activated by protamine.
    Type: Grant
    Filed: July 21, 1995
    Date of Patent: November 10, 1998
    Assignee: Seikagaku Kogyo Kabushiki Kaisha
    Inventors: Hiroko Habuchi, Osami Habuchi, Koji Kimata
  • Patent number: 5817487
    Abstract: Heparan sulfate 2-O-sulfotransferase having the following properties is obtained from, for example, CHO cells:(i) action: sulfate group is transferred from a sulfate group donor selectively to the hydroxyl group at C-2 position of iduronic acid residue of a sulfate group acceptor;(ii) substrate specificity: sulfate group is transferred to heparan sulfate or CDSNS-heparin, but sulfate group is not transferred to chondroitin, chondroitin sulfate, dermatan sulfate, and keratan sulfate;(iii) optimum reaction pH: about pH 5 to 6.5;(iv) optimum ionic strength: about 50 to 200 mM when sodium chloride is used; and(v) inhibition and activation: the activity of the enzyme is increased by protamine, the activity of the enzyme is inhibited by adenosine-3',5'-diphosphate, and the activity of the enzyme is scarcely affected by dithiothreitol at 10 mM or less.
    Type: Grant
    Filed: July 24, 1996
    Date of Patent: October 6, 1998
    Assignee: Seikagaku Kogyo Kabushiki Kaisha
    Inventors: Masashi Kobayashi, Hiroko Habuchi, Osami Habuchi, Koji Kimata